241 related articles for article (PubMed ID: 35433988)
1. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
[TBL] [Abstract][Full Text] [Related]
2. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang C; Fakih M
Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
[TBL] [Abstract][Full Text] [Related]
3. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
4. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
5. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
6. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
7. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S
J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
9. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer.
Li Q; Cheng X; Zhou C; Tang Y; Li F; Zhang B; Huang T; Wang J; Tu S
Front Oncol; 2022; 12():841977. PubMed ID: 35371995
[TBL] [Abstract][Full Text] [Related]
10. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers.
Kang SY; Kim DG; Ahn S; Ha SY; Jang KT; Kim KM
Pathol Res Pract; 2022 May; 233():153874. PubMed ID: 35405622
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor.
Front Immunol; ; . PubMed ID: 37520536
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
